by Plus Therapeutics | Jul 30, 2025 | Uncategorized
In a recent interview with Drug Development & Delivery, Marc Hedrick, M.D., President and CEO of Plus Therapeutics, shared insights into the company’s innovative approach to treating central nervous system (CNS) and solid tumor cancers using targeted...
by Plus Therapeutics | Jul 25, 2025 | Uncategorized
We’re excited to announce that Dr. Andrew Brenner, Principal Investigator for multiple ReSPECT clinical trials, will be going LIVE on Instagram next Tuesday, July 29th at 12:30 PM EST. The conversation will take place on the Game On Glio Podcast Instagram...
by Plus Therapeutics | Jul 24, 2025 | Uncategorized
At Plus Therapeutics, our mission is to radically improve outcomes for patients with central nervous system (CNS) cancers through innovative, targeted radiotherapeutics. In a recent Xtalks Clinical Edge™ feature, our President and CEO, Dr. Marc Hedrick, sat down with...
by Plus Therapeutics | Jul 21, 2025 | Uncategorized
Central nervous system (CNS) cancers—including aggressive diseases like glioblastoma (GBM) and leptomeningeal metastases (LM)—remain among the most challenging cancers to treat. Despite decades of research, treatment options remain limited, and very few therapies have...
by Plus Therapeutics | Jun 30, 2025 | Uncategorized
Plus Therapeutics: Advancing the Future of Radiotherapeutics in Cancer Care At Plus Therapeutics, our mission is clear: to address some of the toughest challenges in oncology by improving the efficacy, precision, and convenience of modern radiotherapeutic treatments....
by Plus Therapeutics | Jun 12, 2025 | Uncategorized
At Plus Therapeutics, our mission is rooted in innovation, precision, and the pursuit of better outcomes for patients facing some of the most aggressive and difficult-to-treat cancers. In a recent interview with AlphaStreet, our President and CEO, Marc Hedrick, M.D.,...
Recent Comments